A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)
Recruiting · Phase 2 · NCT05851924
Conditions: Pancreatic Ductal Adenocarcinoma
At a glance
- Research payments reported, 2025
- $507,427
- U.S. investigators named
- 2
- Sites paid
- 1
- Planned or actual enrollment
- 60
About the trial
- Sponsor
- Memorial Sloan Kettering Cancer Center (with Ipsen, Pancreatic Cancer Research Fund)
- Tested
- NALIRIFOX (drug), AD-XRT and Capecitabine (combination_product)
- Dates
- Started 2023-05-12; completion 2027-09-01
- Results posted
- Not yet
The researchers are doing this study to find out whether using the chemotherapy regimen NALIRIFOX in combination with ablative dose radiation therapy (AD-XRT) and the standard chemotherapy drug capecitabine is an effective treatment approach for people with locally advanced or borderline resectable pancreatic ductal adenocarcinoma (PDAC) before surgery. This type of treatment approach is called total neoadjuvant therapy (TNT). The researchers will also look at whether the sequence of the treatment approach (NALIRIFOX + ADXRT and capecitabine followed by surgery, when it is possible) is effective and causes few or mild side effects in participants. An important purpose of the study is to s…
From ClinicalTrials.gov, last updated 2026-09-17. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Ipsen Biopharmaceuticals, Inc reported $507,427 in research payments for this study in 2025 (2 payments).
Products named: Onivyde
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Memorial Sloan Kettering Hospital $507,427
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.